BRIEF-Sorrento, 3Sbio announce CAR-T joint venture in China
June 7 (Reuters) - Sorrento Therapeutics Inc * 3Sbio will make total contributions of $10 million to joint venture * 3Sbio will initially own 51% of joint venture while TNK will initially hold remaining 49%. * tnk will grant JV exclusive license to CEA CAR-T technology and two additional CARS for cellular therapy for greater china market * Sorrento And 3Sbio Announce CAR-T joint venture in China Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)
